Foralumab Shows Imaging Signal in Progressive MS
Tiziana reported November 2 topline results from randomized, double-blind, placebo-controlled Phase 2a INFORM-MS in non-active secondary progressive multiple sclerosis. The 50-µg intranasal foralumab arm showed a TSPO-PET microglial-activation difference versus placebo at 12 weeks…
